For decades, Medicare explicitly excluded coverage for anti-obesity medications. That changes on July 1, 2026, when the Medicare GLP-1 Bridge Program goes into effect. For the first time, Medicare Part D will cover FDA-approved GLP-1 receptor agonists — including Foundayo (orforglipron) — for chronic weight management. This is a landmark shift that could affect millions of older Americans living with obesity.
Historic Context: Why This Matters
Medicare has never covered anti-obesity medications. The Social Security Act historically excluded "drugs used for anorexia, weight loss, or weight gain" from Part D coverage. Despite obesity affecting over 42% of adults aged 65 and older and driving billions in Medicare spending on related conditions (type 2 diabetes, heart failure, osteoarthritis, sleep apnea), the statute blocked coverage for the very medications that treat the root cause. The GLP-1 Bridge Program is the first federal mechanism to override this exclusion for qualifying beneficiaries.
The Medicare GLP-1 Bridge Program
The Bridge Program is a nationwide initiative effective across all 50 states, the District of Columbia, and U.S. territories. It is not a pilot or demonstration project — it applies to all Medicare Part D plans from day one. The program is administered through existing Part D infrastructure, meaning no new enrollment systems or plan changes are required for beneficiaries.
Eligible Medications
Three GLP-1 medications are covered under the Bridge Program:
- Foundayo (orforglipron) — all available oral formulations (0.8 mg through 17.2 mg)
- Wegovy (semaglutide) — both injection and the newly approved oral tablet form
- Zepbound (tirzepatide) — KwikPen injection formulation only
Only formulations that carry an FDA-approved indication for chronic weight management qualify. Off-label use or compounded versions are not covered.
Eligible Beneficiaries
To access Foundayo through the Bridge Program, you must be enrolled in one of these plan types:
- A standalone Part D prescription drug plan (PDP)
- A Medicare Advantage plan with prescription drug coverage (MA-PD)
Not eligible: Beneficiaries enrolled in Medicare Advantage Private Fee-for-Service (PFFS) plans without drug coverage, or original Medicare without a Part D plan, do not qualify. If you are unsure about your plan type, check your Medicare card or call 1-800-MEDICARE.
Prior Authorization Requirements
Coverage requires prior authorization submitted by your healthcare provider. CMS guidance specifies the following criteria:
- BMI ≥30, OR
- BMI ≥27 with at least one weight-related comorbidity
CMS guidance specifically names heart failure as a qualifying comorbidity, alongside type 2 diabetes, hypertension, dyslipidemia, sleep apnea, and cardiovascular disease. Your provider will need to submit documentation of your BMI and relevant medical conditions when requesting authorization.
Cost to Beneficiary: ~$50/Month
Under the Bridge Program, participating manufacturers provide the medication to CMS at a negotiated net price of $245 per quarter (roughly $82 per month at the wholesale level). After applying the Part D benefit structure, the expected out-of-pocket cost for beneficiaries is approximately $50 per month. This is substantially lower than the LillyDirect self-pay price of $149–$349 per month and comparable to what commercially insured patients pay with the Lilly Savings Card.
How It Works: Step by Step
- Your provider submits a prior authorization to your Part D plan, including your BMI documentation and list of weight-related comorbidities.
- Your Part D plan reviews the PA against CMS criteria. Standard review timelines (72 hours standard, 24 hours expedited) apply.
- If approved, you fill your prescription at any participating pharmacy. LillyDirect, Amazon Pharmacy, and most retail pharmacies are expected to participate.
- Monthly refills continue as long as you remain on the medication and meet ongoing PA requirements (typically annual re-authorization).
Who Is Not Eligible
The following groups are not covered under the Bridge Program:
- Beneficiaries in PFFS plans that do not include prescription drug coverage
- Individuals with BMI below 27 (regardless of comorbidities)
- Individuals with BMI 27–29.9 who do not have a documented weight-related comorbidity
- Beneficiaries enrolled in original Medicare without a Part D plan
If you are not currently in a Part D plan, you can enroll during the next open enrollment period (October 15 – December 7, 2026) to gain access in the following year.
How to Enroll
If you are already enrolled in a Part D plan (PDP or MA-PD), no additional enrollment is needed. You are automatically eligible. Simply have your healthcare provider submit the prior authorization starting July 1, 2026. There is no separate Bridge Program application, no new plan selection, and no additional premium.
Timeline: July 2026 and Beyond
Key dates:
- July 1, 2026: Bridge Program coverage begins. Providers can start submitting PAs.
- Q3–Q4 2026: CMS will assess initial enrollment and utilization data.
- 2027 and beyond: Coverage is expected to continue and expand under the BALANCE Model, which aims to make GLP-1 access a permanent part of Medicare Part D rather than a temporary bridge.
Why This Matters for Medicare Beneficiaries
Approximately 67 million Americans are enrolled in Medicare. Obesity affects 42% of adults 65 and older and is a primary driver of the chronic conditions that consume the largest share of Medicare spending — heart failure, type 2 diabetes, osteoarthritis, and kidney disease. By covering GLP-1 medications like Foundayo, the Bridge Program could reduce downstream costs while improving quality of life for millions of beneficiaries who previously had no affordable access to evidence-based weight management therapy.
Medicare vs Self-Pay vs Commercial Pricing
| Coverage Option | Monthly Cost | Requirements |
|---|---|---|
| Medicare GLP-1 Bridge Program | ~$50 | PA required; BMI ≥30 or ≥27 with comorbidity; PDP or MA-PD enrollment |
| Self-Pay (LillyDirect) | $149–$349 | No insurance required; dose-dependent pricing |
| Commercial Insurance + Lilly Savings Card | $0–$25 | PA + step therapy; savings card not for government insurance |
For a complete breakdown of all Foundayo pricing options, see our Foundayo cost and pricing guide. For details on the Lilly Savings Card program, visit our savings card guide.
Oral GLP-1 tablets now available — from $99/mo
Done with injections? MEDVi offers GLP-1 pills and tablets alongside injectables. Take a 60-second quiz to see your options.
See Oral GLP-1 Options →Medical Disclaimer
Foundayo (orforglipron) is a prescription medication approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. It is not indicated for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. This content is for informational purposes only and does not constitute medical advice. Medicare coverage details are based on CMS guidance available as of April 2026 and may be updated. Always consult your healthcare provider and your Part D plan for the most current information.